Literature DB >> 9508351

Plasma levels of D-dimer and circulating endothelial adhesion molecules in veno-occlusive disease of the liver following allogeneic bone marrow transplantation.

T Südhoff1, M Heins, D Söhngen, V Lenz, A Wehmeier, C Aul, G Meckenstock, W Schneider, H Reinauer, A Heyll.   

Abstract

Veno-occlusive disease (VOD) of the liver is a frequent and life-threatening complication of BMT. Recently, successful treatment by t-PA has been reported but has been compromised by fatal bleeding events. Therefore, t-PA application should be restricted to patients with severe VOD. However, moderate and severe forms of VOD are difficult to distinguish in early stages. We analyzed plasma levels of cross-linked fibrin degradation products (D-dimer) and soluble endothelial adhesion molecules such as sE-selectin, sVCAM-1 and sICAM-1 in 10 consecutive patients undergoing allogeneic BMT to evaluate their use in identifying severe forms of VOD. During the observation period, 4 episodes of VOD occurred, 2 of which were fatal due to early onset of multiorgan failure. Concentrations of D-dimer generally increased after transplantation. However, there was an additional significant increase in D-dimer levels during severe VOD. Thus, D-dimer levels above 1000 microg/l were only found in 2 cases with severe VOD and fatal outcome. When compared with bilirubin concentrations substantial increases of D-dimers appeared earlier during the course of severe VOD. In contrast, VOD episodes were not accompanied by significant increases in sE-selectin, sVCAM-1 and sICAM-1 levels. It is concluded that measurement of D-dimer concentrations may aid accuracy to the early diagnosis of severe VOD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9508351     DOI: 10.1111/j.1600-0609.1998.tb01006.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  1 in total

1.  Prediction of veno-occlusive disease using biomarkers of endothelial injury.

Authors:  Corey Cutler; Haesook T Kim; Shaké Ayanian; Gary Bradwin; Carolyn Revta; Julie Aldridge; Vincent Ho; Edwin Alyea; John Koreth; Philippe Armand; Robert Soiffer; Jerome Ritz; Paul G Richardson; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-23       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.